Fig. 6
From: Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome
Comparison of the time-dependent decrease of neuronal cell surface IgLON5 clusters after treatment with total IgG of two patients with different levels of anti-IgLON5 IgG1 antibodies. On days 1 and 3, treatment with IgG of the patient with the lower level of IgG1 IgLON5 antibodies (7 % of total IgLON5 antibodies) produced a similar decrease of IgLON5 clusters as the IgG of the patient with average level of IgG1 antibodies (23 % of total IgLON5 antibodies). (**p = 0.001, ****p < 0.0001, comparing with control IgG, one-way ANOVA with Bonferroni’s multiple comparison test). In contrast, on day 7, the sample of the patient with lower levels of IgG1 antibodies did not decrease further the levels of IgLON5, whereas the sample of the patient with average level of IgG1 IgLON5 antibodies produced an additional decrease of IgLON5 clusters (****p < 0.0001) that was statistically significant comparing with day 3 (*p = 0.03)